A genetic trawl through the DNA of almost 100,000 people, including 17,000 patients with the most common type of ovarian cancer, has identified 12 new genetic variants that increase risk of developing the disease and confirmed the association of 18 of the previously published variants.
Cambridge scientists have received two of the biggest funding grants ever awarded by Cancer Research UK, with the charity set to invest £40 million over the next five years in two ground-breaking research projects in the city.
Researchers in Cambridge are set to receive a £5m Cancer Research UK’s Catalyst Award to improve the early detection of cancers in GP surgeries. The CanTest team, led by Dr Fiona Walter from the University of Cambridge, will work with researchers in three UK sites and across the globe on a five year project that will help GPs to detect cancers in a primary care setting, enabling patients to benefit from innovative approaches and new technologies, and reducing the burden of referrals.
Cambridge scientists are set to receive a major cash injection from Cancer Research UK, which has announced plans to invest over £41 million over the next five years at the Cancer Research UK Cambridge Centre, one of the University of Cambridge’s Strategic Research Initiatives. The funding will help support ground-breaking work as part of the development of a unique chain of research hubs around the UK.
Two Cambridge institutes have today been confirmed as major research centres by biomedical research charity Wellcome, receiving continued support for a further five years. The centres will be co-funded by Cancer Research UK (CRUK) and the Medical Research Council (MRC) respectively.
A new suite of laboratories aimed at improving outcomes for patients with brain injuries and brain tumours opens today at the University of Cambridge.
A weight loss condition that affects patients with cancer has provided clues as to why cancer immunotherapy – a new approach to treating cancer by boosting a patient’s immune system – may fail in a substantial number of patients.
A small molecule that can turn short-lived ‘killer T-cells’ into long-lived, renewable cells that can last in the body for a longer period of time, activating when necessary to destroy tumour cells, could help make cell-based immunotherapy a realistic prospect to treat cancer.